Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up.
BACKGROUND
Several disorders have been attributed to measles-mumps-rubella (MMR) vaccination during the past decade. The aim of this prospective follow-up study was to identify serious adverse events causally related to MMR vaccination.


METHODS
When the MMR vaccination program was launched in Finland in 1982, a countrywide surveillance system was set up to detect serious adverse events associated with MMR. To obtain detailed case histories vaccinees' clinical charts were reviewed. Serum samples were analyzed to trace concurrent infections.


METHODS
All hospitals and health centers in Finland from 1982 through 1996.


RESULTS
Immunization of 1.8 million individuals and consumption of almost 3 million vaccine doses by the end of 1996 gave rise to 173 potentially serious reactions claimed to have been caused by MMR vaccination. In all, 77 neurologic, 73 allergic and 22 miscellaneous reactions and 1 death were reported, febrile seizure being the most common event. However, 45% of these events proved to be probably caused or contributed by some other factor, giving an incidence of serious adverse events with possible or indeterminate causal relation with MMR vaccination of 5.3 per 100,000 vaccinees or 3.2 per 100,000 vaccine doses.


CONCLUSIONS
Causality between immunization and a subsequent untoward event cannot be estimated solely on the basis of a temporal relation. Comprehensive analysis of the reported adverse reactions established that serious events causally related to MMR vaccine are rare and greatly outweighed by the risks of natural MMR diseases.
Patja
A
A
Hospital for Children and Adolescents, Helsinki University Central Hospital, Finland. annamari.patja@hus.fi
Davidkin
I
I
Kurki
T
T
Kallio
M J
MJ
Valle
M
M
Peltola
H
H
D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D002648:Child; D002675:Child, Preschool; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects*; D009422:Nervous System Diseases / Q000209:etiology; D011446:Prospective Studies; D014611:Vaccination
D022542:Measles-Mumps-Rubella Vaccine